Here are the 424B prospectus supplements from Oculis Holding AG Warrants (OCSAW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow OCSAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCSAW filings page.
Oculis Holding AG increased its at-the-market offering capacity to an aggregate offering price of up to $125,000,000 of ordinary shares under an amended sales agreement with Leerink Partners. The previous agreement covered an aggregate offering price of up to $100,000,000; Oculis had sold $61,323,500 under the agreement as of November 3, 2026.
Sales may be made through or to Leerink Partners as sales agent or principal, subject to placement notices and mutually agreed terms. Oculis may set a minimum sale price or suspend sales with proper notice. Oculis will receive net proceeds and pay commissions of up to 3.0% of gross proceeds. Estimated offering expenses excluding commissions are approximately $1,500,000; separate expense reimbursements are capped at $55,000 for specified expenses and $25,000 per calendar quarter for certain legal costs.